Products for Research Use Only
RegisterLogin

JG26

CAT: 0804-HY-120852-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-120852-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII -induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases[1][2][3][4][5][6].
CAS Number
1464910-32-4
UNSPSC
12352005
Target
Angiotensin-converting Enzyme (ACE) ; EGFR; ERK; MMP; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/jg26.html
Purity
98.14
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C([C@@H](CCCNC(N)=O)NS(=O)(C1=CC=C(C=C1)OCC2=CC(Br)=CC(Br)=C2)=O)NO
Molecular Formula
C19H22Br2N4O6S
Molecular Weight
594.27
References & Citations
[1]Doretta Cuffaro, et al. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. ACS Med Chem Lett. 2021 Oct 8;12 (11) :1787-1793.|[2]Gentili V, et al. JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro. Pharmacol Rep. 2025 Feb;77 (1) :260-273. |[3]Zocchi MR, et al. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology. 2015 Dec 29;5 (5) :e1123367.|[4]Cuffaro D, et al. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. ACS Med Chem Lett. 2021 Oct 8;12 (11) :1787-1793.|[5]Li K, et al. Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer. J Exp Clin Cancer Res. 2024 Feb 27;43 (1) :59. |[6]Kawai T, et al. Pharmacological Inhibition of ADAM17 by a Human-Cross Reactive Antibody and Selective Inhibitor JG26 Prevents Vascular Fibrosis Induced by Angiotensin II in vivo and in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36 (suppl_1) : A557-A557.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ADAM10; ADAM17; ADAM8; MMP-12; MMP-14; MMP-8; MMP-9

Alternative Products

CatalogName
T27654-01JG26
A24194-50JG26 50mg
A24194-1JG26 1mg
A24194-10JG26 10mg
A24194-5JG26 5mg

Popular Products